heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
Company profile
Ticker
HRTX
Exchange
Website
CEO
Barry Quart
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADVANCED POLYMER SYSTEMS INC /DE/, AP PHARMA INC /DE/
SEC CIK
Corporate docs
IRS number
942875566
HRTX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
19 Apr 24
8-K
Departure of Directors or Certain Officers
21 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
12 Mar 24
8-K
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
24 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
8-K
Other Events
22 Dec 23
8-K
Departure of Directors or Certain Officers
21 Dec 23
8-K
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
Transcripts
HRTX
Earnings call transcript
2023 Q4
12 Mar 24
HRTX
Earnings call transcript
2023 Q3
14 Nov 23
HRTX
Earnings call transcript
2023 Q2
14 Aug 23
HRTX
Earnings call transcript
2023 Q1
11 May 23
HRTX
Earnings call transcript
2022 Q4
23 Mar 23
HRTX
Earnings call transcript
2022 Q3
9 Nov 22
HRTX
Earnings call transcript
2022 Q2
9 Aug 22
HRTX
Earnings call transcript
2022 Q1
9 May 22
HRTX
Earnings call transcript
2021 Q4
1 Mar 22
HRTX
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
4
Ira Duarte
19 Apr 24
4
William P Forbes
19 Apr 24
4
Craig A Collard
19 Apr 24
4
Craig A Collard
5 Apr 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FRANKLIN RESOURCES INC
6 Feb 24
4
Waage Christian
19 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 34.86 mm | 34.86 mm | 34.86 mm | 34.86 mm | 34.86 mm | 34.86 mm |
Cash burn (monthly) | (no burn) | 1.30 mm | 8.31 mm | 10.06 mm | 3.06 mm | 8.23 mm |
Cash used (since last report) | n/a | 8.98 mm | 57.49 mm | 69.61 mm | 21.17 mm | 56.94 mm |
Cash remaining | n/a | 25.88 mm | -22.63 mm | -34.75 mm | 13.69 mm | -22.09 mm |
Runway (months of cash) | n/a | 19.9 | -2.7 | -3.5 | 4.5 | -2.7 |
Institutional ownership, Q3 2023
81.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 140 |
Opened positions | 14 |
Closed positions | 22 |
Increased positions | 37 |
Reduced positions | 41 |
13F shares | Current |
---|---|
Total value | 120.32 bn |
Total shares | 122.14 mm |
Total puts | 5.90 k |
Total calls | 11.30 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Rubric Capital Management | 26.71 mm | $27.51 bn |
Vanguard | 8.17 mm | $8.41 bn |
Baker Bros. Advisors | 8.13 mm | $8.38 bn |
BLK Blackrock | 8.13 mm | $8.37 bn |
Velan Capital Investment Management | 6.99 mm | $7.20 bn |
BEN Franklin Resources | 6.96 mm | $7.17 bn |
JPM JPMorgan Chase & Co. | 6.81 mm | $7.01 bn |
Clearline Capital | 6.15 mm | $6.33 bn |
Great Point Partners | 4.74 mm | $4.88 bn |
Palisade Capital Management | 4.11 mm | $4.23 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Apr 24 | Collard Craig A | Common Stock | Option exercise | Acquire M | No | No | 0 | 13,797 | 0.00 | 262,793 |
19 Apr 24 | Ira Duarte | Common Stock | Payment of exercise | Dispose F | No | No | 2.64 | 1,122 | 2.96 k | 87,752 |
19 Apr 24 | Ira Duarte | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,874 | 0.00 | 88,874 |
19 Apr 24 | Ira Duarte | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,874 | 0.00 | 58,115 |
19 Apr 24 | William P Forbes | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,874 | 0.00 | 82,874 |
19 Apr 24 | William P Forbes | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,874 | 0.00 | 58,115 |
3 Apr 24 | Collard Craig A | Common Stock | Option exercise | Acquire M | No | No | 0 | 62,500 | 0.00 | 248,996 |
3 Apr 24 | Collard Craig A | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 62,500 | 0.00 | 187,500 |
19 Jan 24 | Collard Craig A | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 13,797 | 0.00 | 206,953 |
19 Jan 24 | Christian Waage | Common Stock | Grant | Acquire A | No | No | 0 | 13,948 | 0.00 | 66,180 |
News
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
23 Apr 24
Capital One Initiates Coverage On Heron Therapeutics with Overweight Rating, Announces Price Target of $6
23 Apr 24
Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
11 Apr 24
Why Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?
13 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
13 Mar 24
Press releases
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
24 Apr 24
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
11 Apr 24
Biotech Finds Mid-Week Success Following Q4 Earnings Release
13 Mar 24
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
12 Mar 24